Current trends in regional therapy for melanoma: Lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution

Journal of the American College of Surgeons

Volumn 213, Issue 2, 2011, Pages 306-316

  Raymond, Amanda K ^a   Beasley, Georgia M ^a   Broadwater, Gloria ^a   Augustine, Christina K ^a   Padussis, James C ^a   Turley, Ryan ^a   Peterson, Bercedis ^a   Seigler, Hilliard ^a   Pruitt, Scott K ^a   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Common Terminology Criteria for Adverse Events; complete response; CPK; CR; creatine phosphokinase; CTCAE; HILP; hyperthermic isolated limb perfusion; IBW; ideal body weight; ILI; isolated limb perfusion; NE; not evaluable; partial response; PD; PR; progressive disease; SD; stable disease; time to in field progression; TTiP

Indexed keywords

DACTINOMYCIN; MELPHALAN; SORAFENIB;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; EVENING DOSAGE; FEMALE; HUMAN; HYPERTHERMIC ISOLATED LIMB PERFUSION; INTERMETHOD COMPARISON; ISOLATED LIMB INFUSION; LIMB PERFUSION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORNING DOSAGE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURGICAL INFECTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LOWER EXTREMITY; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SKIN NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960836758     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2011.03.013     Document Type: Article

References (39)

1. C.M. Balch, A.N. Houghton, and L.J. Peters Cutaneous melanoma V.T. Devita, S. Hellman, S.A. Rosenberg, Cancer: principles and practice of oncology 4th ed. 1993 JB Lippincott Philadelphia 1612
2. T.M. Pawlik, M.I. Ross, and M.M. Johnson Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy Ann Surg Oncol 12 2005 587 596 (Pubitemid 41126088)
3. O. Creech Jr, E.T. Krementz, R.F. Ryan, and J.N. Winblad Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit Ann Surg 148 1958 616 632
4. J.M. Klaase, B.B. Kroon, and A.N. van Geel Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan Surgery 115 1994 39 45 (Pubitemid 24039210)
5. D.R. Minor, R.E. Allen, and D. Alberts A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma Cancer 55 1985 2638 2644 (Pubitemid 15092151)
6. F. Di Filippo, A. Calabro, and D. Giannarelli Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion Cancer 63 1989 2551 2561 (Pubitemid 19152772)
7. B.B. Kroon, A.N. Van Geel, C. Benckhuijsen, and J. Wieberdink Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs Anticancer Res 7 1987 441 442 (Pubitemid 17151928)
8. W.R. Cornett, L.M. McCall, and R.P. Petersen Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020 J Clin Oncol 24 2006 4196 4201 (Pubitemid 46622299)
9. G.M. Beasley, R.P. Petersen, and J. Yoo Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion Ann Surg Oncol 15 2008 2195 2205
10. A.I. Skene, A.S. Bulman, and T.R. Williams Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb Br J Surg 77 1990 765 767 (Pubitemid 20236115)
11. D.L. Fraker, and A.M. Eggermont Cutaneous melanoma 14th ed. 2003 Quality Medical St Louis, MO 405 418
12. G.M. Beasley, A. Caudle, and R.P. Petersen A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US J Am Coll Surg 208 2009 706 715 discussion 715-717
13. H.M. Kroon, M. Moncrieff, P.C. Kam, and J.F. Thompson Outcomes following isolated limb infusion for melanoma A 14-year experience Ann Surg Oncol 15 2008 3003 3013
14. G.M. Beasley, H.M. Kroon, and M.I. Ross Isolated limb infusion C.M. Balch, A.N. Houghton, A.J. Soper, Cutaneous melanoma 5th ed. 2009 Quality Medical Publishing St Louis, MO 541 562
15. B.C. Vrouenraets, J.M. Klaase, O.E. Nieweg, and B.B. Kroon Toxicity and morbidity of isolated limb perfusion Semin Surg Oncol 14 1998 224 231 (Pubitemid 28146514)
16. C.M. Balch, J.E. Gershenwald, and S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
17. J. Wieberdink, C. Benckhuysen, and R.P. Braat Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions Eur J Cancer Clin Oncol 18 1982 905 910 (Pubitemid 13147887)
18. N. McMahon, G.M. Beasley, and G. Sanders A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma J Clin Oncol 27 2009 Abstract no. 9065
19. G.M. Beasley, N. McMahon, and G. Sanders A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma Cancer 115 2009 4766 4774
20. G.M. Beasley, J.C. Riboh, and C.K. Augustine A prospective multi-center phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion (M-ILI) in patients with advanced extremity melanoma J Clin Oncol 29 2011 1210 1215
21. T.A. Aloia, E. Grubbs, and M. Onaitis Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response Arch Surg 140 2005 1115 1120 (Pubitemid 41668683)
22. J.F. Thompson, J.A. Hunt, K.F. Shannon, and P.C. Kam Frequency and duration of remission after isolated limb perfusion for melanoma Arch Surg 132 1997 903 907 (Pubitemid 27344144)
23. N. McMahon, T.Y. Cheng, and G.M. Beasley Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 16 2009 953 961
24. T.Y. Cheng, E. Grubbs, and O. Abdul-Wahab Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion Am J Surg 186 2003 460 467 (Pubitemid 37352828)
25. A. Sanki, P.C. Kam, and J.F. Thompson Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology Ann Surg 245 2007 591 596 (Pubitemid 46555663)
26. F.J. Lejeune, T. Deloof, and P. Ewalenko Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan Recent Results Cancer Res 86 1983 268 276
27. H.S. Koops, M. Vaglini, and S. Suciu Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593 J Clin Oncol 16 1998 2906 2912
28. Y. Xing, X. Lu, E.C. Pua, and P. Zhong The effect of high intensity focused ultrasound treatment on metastases in a murine melanoma model Biochem Biophys Res Commun 375 2008 645 650
29. D.S. Reintgen, S. Pendas, and J. Jakub Regional therapy for recurrent metastatic melanoma confined to the extremity: hyperthermic isolated limb perfusion vs. isolated limb infusion Ann Surg Oncol 16 Suppl 1 2009 S10
30. S.W. Taber, and H.C. Polk Jr Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma Ann Surg Oncol 4 1997 440 445 (Pubitemid 127725521)
31. A.A. Santillan, K.A. Delman, and G.M. Beasley Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis Ann Surg Oncol 16 2009 2570 2578
32. P. Lindner, A. Doubrovsky, P.C. Kam, and J.F. Thompson Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma Ann Surg Oncol 9 2002 127 136 (Pubitemid 34259697)
33. A.P. Coleman, G.M. Beasley, and N. McMahon Augmenting regional therapy with targeted agents: a phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity Ann Surg Oncol 18 Suppl 1 2011 S114 S115
34. H.M. Kroon, D.Y. Lin, P.C. Kam, and J.F. Thompson Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma Cancer 115 2009 1932 1940
35. D.J. Grunhagen, B. van Etten, and F. Brunstein Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure Ann Surg Oncol 12 2005 609 615 (Pubitemid 41126090)
36. E.M. Noorda, B.C. Vrouenraets, and O.E. Nieweg Repeat isolated limb perfusion with TNF-alpha and melphalan for recurrent limb melanoma after failure of previous perfusion Eur J Surg Oncol 32 2006 318 324
37. M.J. Reinhardt, A.Y. Joe, and U. Jaeger Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients J Clin Oncol 24 2006 1178 1187 (Pubitemid 46638816)
38. T.S. Aukema, R.A. Valdes Olmos, and M.W. Wouters Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases Ann Surg Oncol 17 2010 2773 2778
39. D.W. Ollila Complete metastasectomy in patients with stage IV metastatic melanoma Lancet Oncol 7 2006 919 924 (Pubitemid 44615951)